← Leaderboards
Philip W. Tucker
University Of Texas Austin
$8,273,151
Attributed
$8,273,151
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2005–12$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$8,273,151 · 7
By mechanism
R01$7,109,759 · 5
R37$745,392 · 1
R21$418,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Austin
Same institution · by research overlap
- Paul D Gottlieb$1,383,000
Others in their field
Top investigators on “Transcription Factor”
- Michael P Snyder · Yale University$110,571,583
- Richard M Myers · Hudson-Alpha Institute For Biotechnology$57,320,347
- Eric J Nestler · Icahn School Of Medicine At Mount Sinai$55,523,574
- Angela M. Gronenborn · Diabetes, Digestive, Kidney Diseases$45,640,184
- Richard K. Wilson · Washington University$45,224,621
- Deborah Nickerson · University Of Washington$35,131,320
Research focus
Transcription FactorLaboratory MouseGene ExpressionB LymphocyteGene TargetingNeoplasm /Cancer GeneticsEnhancersB-LymphocytesImmunoglobulin GenesPathway InteractionsGene Induction /RepressionDna Binding ProteinBinding (Molecular Function)Tissue /Cell CultureProtein IsoformsNuclear MatrixProtein Protein InteractionStagingMediatingMalignant - DescriptorImmunogeneticsFunctional DisorderKnock-OutDna Binding
Grant awards (31)
MAR Mediated Control of The IgH Enhancer$249,638
R01 · FY2012 · CA · contact PI
MAR Mediated Control of The IgH Enhancer$249,638
R01 · FY2011 · CA · contact PI
MAR Mediated Control of The IgH Enhancer$257,359
R01 · FY2010 · CA · contact PI
A TRANSCRIPTION FACTOR WITHIN LIPID RAFTS MODULATES B CELL SIGNALING VIA THE BCR$190,000
R21 · FY2010 · AI · contact PI
MAR Mediated Control of The IgH Enhancer$257,359
R01 · FY2009 · CA · contact PI
A TRANSCRIPTION FACTOR WITHIN LIPID RAFTS MODULATES B CELL SIGNALING VIA THE BCR$228,000
R21 · FY2009 · AI · contact PI
ROLE OF eARIDs IN LYMPHOCYTE FUNCTION AND DEVELOPMENT$279,050
R01 · FY2008 · AI · contact PI
MAR Mediated Control of The IgH Enhancer$257,359
R01 · FY2008 · CA · contact PI
ROLE OF eARIDs IN LYMPHOCYTE FUNCTION AND DEVELOPMENT$284,454
R01 · FY2007 · AI · contact PI
MAR MEDIATED CONTROL OF THE IgH ENHANCER$75,000
R01 · FY2007 · CA · contact PI
Role of Bop in Cardiac Development and Function$367,164
R01 · FY2006 · HL · contact PI
ROLE OF eARIDs IN LYMPHOCYTE FUNCTION AND DEVELOPMENT$292,950
R01 · FY2006 · AI · contact PI
MAR MEDIATED CONTROL OF THE IgH ENHANCER$260,726
R01 · FY2006 · CA · contact PI
Role of Bop in Cardiac Development and Function$376,000
R01 · FY2005 · HL
ROLE OF eARIDs IN LYMPHOCYTE FUNCTION AND DEVELOPMENT$300,000
R01 · FY2005 · AI
INTERACTION OF CIS-ACTING ELEMENTS IN CD8 REGULATION$298,000
R01 · FY2005 · AI
MAR MEDIATED CONTROL OF THE IgH ENHANCER$267,000
R01 · FY2005 · CA
BCL11 GENES IN NORMAL AND MALIGNANT B CELL DEVELOPMENT$236,250
R01 · FY2005 · CA
Role of Bop in Cardiac Development and Function$376,000
R01 · FY2004 · HL
INTERACTION OF CIS-ACTING ELEMENTS IN CD8 REGULATION$298,000
R01 · FY2004 · AI
MAR MEDIATED CONTROL OF THE IgH ENHANCER$267,000
R01 · FY2004 · CA
BCL11 GENES IN NORMAL AND MALIGNANT B CELL DEVELOPMENT$236,250
R01 · FY2004 · CA
ROLE OF eARIDs IN LYMPHOCYTE FUNCTION AND DEVELOPMENT$150,000
R01 · FY2004 · AI
MAR MEDIATED CONTROL OF THE IgH ENHANCER$267,000
R01 · FY2003 · CA
BCL11 GENES IN NORMAL AND MALIGNANT B CELL DEVELOPMENT$236,250
R01 · FY2003 · CA
MAR MEDIATED CONTROL OF THE IgH ENHANCER$267,000
R01 · FY2002 · CA
BCL11 GENES IN NORMAL AND MALIGNANT B CELL DEVELOPMENT$236,250
R01 · FY2002 · CA
HEAVY CHAIN GENE ORGANIZATION IN TRANSFORMED B LYMPHOCYT$378,205
R37 · FY2001 · AI
BCL11 GENES IN NORMAL AND MALIGNANT B CELL DEVELOPMENT$236,250
R01 · FY2001 · CA
HEAVY CHAIN GENE ORGANIZATION IN TRANSFORMED B LYMPHOCYT$367,187
R37 · FY2000 · AI
MAR MEDIATED GENETIC SWITCH FOR IGH ENHANCER CONTROL$231,812
R01 · FY2000 · CA